Group A Streptococcus and Necrotizing Fasciitis

Epidemiology and Clinical Significance

Group A Streptococcus is a primary pathogen responsible for monomicrobial necrotizing fasciitis, with mortality rates ranging from 30% to 70% in patients who develop hypotension and organ failure, according to the Infectious Diseases Society of America 1, 2
Nearly 50% of cases occur without an identifiable portal of entry, developing at sites of nonpenetrating trauma such as bruises or muscle strains, as reported by the Clinical Infectious Diseases journal 2
Cases arising after varicella or trivial injuries are almost always due to S. pyogenes, with a high degree of evidence from the Clinical Infectious Diseases journal 2, 4

Severe pain may be the initial and most prominent symptom, often with minimal cutaneous evidence due to the deep fascial involvement, making diagnosis challenging, as noted by the Clinical Infectious Diseases journal 2
Critical diagnostic features include a hard, wooden feel of subcutaneous tissue extending beyond apparent skin involvement, with a moderate level of evidence from the Clinical Infectious Diseases journal 4
Systemic toxicity with altered mental status is a key diagnostic feature, with a high degree of evidence from the Clinical Infectious Diseases journal 4
Skin necrosis or ecchymoses are common findings, as reported by the Clinical Infectious Diseases journal, with a moderate level of evidence 5

Prompt surgical consultation and aggressive debridement within the first 24-48 hours is the cornerstone of treatment and the most significant factor reducing mortality, with a high degree of evidence from the Clinical Infectious Diseases journal 1, 6
Return to operating room every 24-36 hours after initial debridement until no further necrosis is present, as recommended by the Clinical Infectious Diseases journal, with a moderate level of evidence 6
Aggressive fluid administration is essential as these wounds discharge copious tissue fluid, with a moderate level of evidence from the Clinical Infectious Diseases journal 6

For documented or highly suspected Group A streptococcal necrotizing fasciitis, the recommended regimen is penicillin (2-4 million units every 4-6 hours IV) PLUS clindamycin (600-900 mg every 8 hours IV), with a high degree of evidence from the Clinical Infectious Diseases journal 1, 3, 6
Clindamycin suppresses streptococcal toxin production and modulates cytokine production, demonstrating superior efficacy compared to β-lactam antibiotics alone, with a moderate level of evidence from the Clinical Infectious Diseases journal 5
Penicillin monotherapy should never be used alone for streptococcal necrotizing fasciitis, as recommended by the Clinical Infectious Diseases journal, with a high degree of evidence 6

Continue antimicrobial therapy until ALL three criteria are met: no further surgical debridement is necessary, patient demonstrates obvious clinical improvement, and fever has been absent for 48-72 hours, with a moderate level of evidence from the Clinical Infectious Diseases journal 6

Bacteremia is a factor associated with increased mortality, with a moderate level of evidence from the Clinical Infectious Diseases journal 5
Shock at presentation is a critical prognostic factor, with a high degree of evidence from the Clinical Infectious Diseases journal 4
Duration of symptoms <5 days suggests rapid progression and is associated with increased mortality, with a moderate level of evidence from the Clinical Infectious Diseases journal 5
Low white blood cell count, low platelet count, and prolonged prothrombin time are also associated with increased mortality, with a moderate level of evidence from the Clinical Infectious Diseases journal 5